In a significant move within the healthcare tech industry, ScreenPoint Medical has announced its acquisition of Biomediq A/S, a pioneer in quantitative imaging biomarkers. This acquisition promises to enhance ScreenPoint’s capabilities in breast cancer risk assessment, leveraging their industry-leading Breast AI, Transpara. This merger aims to integrate advanced imaging technologies to improve early cancer detection rates and refine risk predictions.
ScreenPoint Acquires Biomediq: A Strategic Move
Joining forces after a decade of collaboration, ScreenPoint Medical has acquired Biomediq A/S to deepen its breast cancer detection and prediction capabilities. Biomediq’s expertise in automatic computer-based analysis of mammograms will complement ScreenPoint’s Transpara, aiming to provide a more accurate and consistent assessment of breast cancer risks. This strategic expansion is set to not only expand ScreenPoint’s product offerings but also enhance the predictive power of their algorithms.
Enhanced Breast Cancer Risk Prediction Tools
The merger is highlighted by the integration of Biomediq’s Mammographic Texture Risk biomarker with ScreenPoint’s Transpara Detection and Density tools. Recent studies have shown that combining these technologies enhances the prediction accuracy for breast cancer risks. Such advancements are crucial for the early detection of interval cancers, potentially doubling the rates of early detection by identifying cancer in between regular screening visits. These tools aim to provide a robust framework for radiologists, offering a ‘second pair’ of eyes and reducing recall rates significantly.
The Future of Breast AI with Transpara 2.1
ScreenPoint is pushing the boundaries of breast imaging technology with the release of Transpara 2.1, an update crafted from extensive global user feedback and additional training. This version not only supports automated breast density assessment but introduces a groundbreaking temporal comparison feature, allowing radiologists to compare current studies with up to three prior mammograms over a six-year period. Both CE marked and FDA cleared, these tools are setting new standards in the field of breast cancer screening and diagnostics.
The acquisition of Biomediq positions ScreenPoint Medical at the forefront of breast cancer diagnostics technology. Through strategic collaboration and technology integration, ScreenPoint aims to revolutionize breast cancer screening and enhance the quality of care delivered to women globally, making early detection more accessible and reliable. The future holds promise for improved health outcomes through high-tech, risk-stratified screening processes.
Don’t miss our latest Startup News: FATHOM EPR Spectrometer Transforms Protein Research
